eMed raises $200 million to advance agentic AI platform targeting employer healthcare costs

Miami-based telehealth company eMed has closed a $200 million (€174.19 million) Series A funding round, pushing its valuation beyond $2 billion (€1.74 billion) as the company intensifies its push into AI-driven population health management and employer-focused healthcare cost reduction, according to Reuters.

The round was led by Aon Consulting and attracted a roster of high-profile backers including former X chief executive Linda Yaccarino, who also serves as eMed's CEO, Paragon Biosciences founder and Chief Executive Jeff Aronin, and seven-time Super Bowl champion Tom Brady, who holds the title of founding chief wellness officer.

eMed's commercial model centres on partnering with employers and government payers to manage GLP-1 usage, a class of drugs prescribed for obesity and diabetes whose cost has historically constrained broader insurance coverage. The GLP-1 market is widely projected to reach $150 billion (€130.64 billion) in annual sales by the next decade, drawing intensifying competition among telehealth platforms.

Yaccarino said: "The raise confirms eMed momentum and establishes us as the definitive company for population health and helping employers break the runaway health care costs and break their cost curve."

Proceeds will fund further development of eMed's agentic AI platform and support the launch of a new healthcare payment model designed to reduce costs for employer clients.

Founded in 2020, eMed initially gained traction through at-home COVID-19 testing before expanding into broader diagnostics. The company has since repositioned squarely around population health management and AI-enabled care delivery.

Access the full details of eMed's funding round and growth strategy in the complete report by Reuters.